Here’s the earnings call and Q&A reviewed.
Earnings call transcript: InMode Q3 2025 beats expectations, stock rises By Investing.com
Inmode is rising sharply in pre-market.
This doesn’t mean much yet, but I started investigating whether there’s any news. I didn’t find any, but there is discussion about the topic.
Apparently, a takeover bid is coming, or at least it’s being speculated. The source is not very reliable, so we’ll see how it goes.
If two groups start competing against each other, that would be great. The price should rise significantly more.
The link and article below were found on Stocktwits. No information on reliability, but it relates directly to that acquisition offer topic.
The article is in Hebrew; I skimmed it with a browser translator. Here is likely the gist regarding the price:
A foreign investment fund is in advanced talks to acquire the Israeli medical aesthetics company InMode, in a deal that reflects a value of about $1.1 billion for the company, a premium of about 25% over the value at which it is traded on the US Nasdaq stock exchange, which stands at $882 million.
Today was Inmode’s earnings release. It’s a bit soft, as profitability has weakened significantly and the share price will likely dip a bit today.
What am I doing? Nothing, just holding, as I have patience. In my opinion, the risk-reward ratio is good. In a worst-case scenario, Inmode generates a small loss, but in a good scenario, it’s a multibagger within a few years.
At least revenue grew, but that alone isn’t particularly heartening. Additionally, the CFO and a board member are leaving. The silver lining regarding the CFO’s departure is that he will stay on for at least six months to ensure a smoother transition.
First Quarter 2026 Highlights:
● Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.
● Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.
● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.
● Total cash position of $537.2 million as of March 31, 2026, including cash and cash equivalents, marketable securities and short-term bank deposits.
● As of March 31, 2026, we completed the repurchase of 2.55 million ordinary shares pursuant to our share repurchase program, returning $34.8 million of capital to shareholders ($3.6 million of which was paid during the second quarter of 2026).
● Announced CFO transition; Yair Malca steps down and will support an orderly transition as a consultant.
● Board transition: Dr. Michael Anghel resigns; Dr. Hadar Ron appointed Interim Chair of the Board.
2026 Financial Outlook
Management provided an outlook for the full fiscal year ending December 31, 2026. Based on current estimates, management expects:
Revenues between $365 million and $375 million
*Non-GAAP gross margin between 74% and 76%
*Non-GAAP income from operations to be between $73 million and $78 million
*Non-GAAP earnings per diluted share between $1.33 and $1.38